Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grazia Graziani

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
Pharmacological Research|September 1, 2018
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitorsPedro Miguel Lacal, Grazia Graziani
Chemotherapy|November 3, 2015
EditorialGiorgio Minotti, Grazia Graziani, Giovanni Delogu
Pharmacological Research|February 16, 2002
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitorsLucio Tentori, Ilaria Portarena, Grazia Graziani
Pharmacological Research|May 25, 2005
PARP-1 inhibition to treat cancer, ischemia, inflammationGrazia Graziani, Fiorenzo Battaini, Jie Zhang
Pharmacological Research|September 21, 2011
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancerGrazia Graziani, Lucio Tentori, Pierluigi Navarra
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Clinical applications of telomerase in cancer treatmentIsabella Faraoni, Enzo Bonmassar, Grazia Graziani
Pharmacology & Therapeutics|January 6, 2022
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potentialClaudia Ceci, Pedro Miguel Lacal, Grazia Graziani
Trends in Pharmacological Sciences|November 12, 2013
Challenging resistance mechanisms to therapies for metastatic melanomaLucio Tentori, Pedro Miguel Lacal, Grazia Graziani
Experientia Supplementum (2012)|February 15, 2022
Monoclonal Antibodies to CTLA-4 with Focus on IpilimumabGrazia Graziani, Lucia Lisi, Lucio Tentori, et al.
Nanotechnology|May 8, 2020
Strategies to improve ellagic acid bioavailability: from natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriersClaudia Ceci, Grazia Graziani, Isabella Faraoni, et al.
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
Pharmacological Research|September 1, 2018
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitorsPedro Miguel Lacal, Grazia Graziani
Chemotherapy|November 3, 2015
EditorialGiorgio Minotti, Grazia Graziani, Giovanni Delogu
Pharmacological Research|February 16, 2002
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitorsLucio Tentori, Ilaria Portarena, Grazia Graziani
Pharmacological Research|May 25, 2005
PARP-1 inhibition to treat cancer, ischemia, inflammationGrazia Graziani, Fiorenzo Battaini, Jie Zhang
Pharmacological Research|September 21, 2011
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancerGrazia Graziani, Lucio Tentori, Pierluigi Navarra
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Clinical applications of telomerase in cancer treatmentIsabella Faraoni, Enzo Bonmassar, Grazia Graziani
Pharmacology & Therapeutics|January 6, 2022
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potentialClaudia Ceci, Pedro Miguel Lacal, Grazia Graziani
Trends in Pharmacological Sciences|November 12, 2013
Challenging resistance mechanisms to therapies for metastatic melanomaLucio Tentori, Pedro Miguel Lacal, Grazia Graziani
Experientia Supplementum (2012)|February 15, 2022
Monoclonal Antibodies to CTLA-4 with Focus on IpilimumabGrazia Graziani, Lucia Lisi, Lucio Tentori, et al.
Nanotechnology|May 8, 2020
Strategies to improve ellagic acid bioavailability: from natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriersClaudia Ceci, Grazia Graziani, Isabella Faraoni, et al.
Pageof 13